Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.2
Journals
Vaccines
Special Issues
HPV Vaccination and Primary HPV Screening
share announcement

HPV Vaccination and Primary HPV Screening

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 395

Special Issue Editors

Dr. Antonio Di Lorenzo

E-Mail
Guest Editor
Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza G. Cesare 11, 70121 Bari, Italy
Interests: vaccinology; epidemiology of infectious diseases; health communication
Dr. Pasquale Stefanizzi

E-Mail
Guest Editor
Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza G. Cesare 11, 70121 Bari, Italy
Interests: adverse events following immunization; vaccinology; infectious disease control and prevention
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit your contributions to this Special Issue which focuses on HPV vaccination and primary HPV screening. Human papillomavirus (HPV) is the most common sexually transmitted pathogen worldwide. Most sexually active individuals encounter HPV at least once in their lifetime. Vaccination is the primary measure to mitigate HPV’s impact on the population. HPV vaccination presents specific challenges. Although a gender-neutral approach has been recommended, special attention must be given to high-risk groups. Achieving equitable access to vaccination, ensuring proper training for healthcare workers, improving health literacy, and enhancing effective risk communication are essential objectives.

This Special Issue aims to gather new evidence regarding HPV vaccination and HPV-related cancer screening, including the current state of the art and suggestions for new approaches, perspectives, and areas for investigation. We welcome original research articles and reviews. Research areas may include the following:

  • New HPV vaccines and innovative HPV vaccine-delivery systems;
  • The efficacy, effectiveness, and safety of HPV vaccination;
  • Barriers and facilitators to HPV vaccination uptake;
  • Factors contributing to HPV-specific vaccine hesitancy;
  • New tools/technologies for HPV screening;
  • Evaluating the immunogenicity of a single-dose HPV vaccination schedule;
  • The long-term immunogenicity of HPV vaccines.

Dr. Antonio Di Lorenzo
Dr. Pasquale Stefanizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sexually transmitted diseases
  • HPV vaccination
  • cervical cancer screening
  • vaccine hesitancy
  • vaccine safety
  • vaccine effectiveness

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1284 KiB  
Article
Prevalence of Vaccine-Covered and Non-Covered HPV Genotypes Among Unvaccinated Women in Ankara: A Single-Center Study
by Ayfer Bakır and Mehmet Alican Sapmaz
Vaccines 2025, 13(6), 640; https://doi.org/10.3390/vaccines13060640 - 13 Jun 2025
Viewed by 129
Abstract
Background/Objectives: Understanding the regional distribution of human papillomavirus (HPV) genotypes is essential for guiding effective vaccination and screening strategies. This study aimed to assess the prevalence and distribution of HPV genotypes among unvaccinated women aged 30 years and older undergoing routine screening in [...] Read more.
Background/Objectives: Understanding the regional distribution of human papillomavirus (HPV) genotypes is essential for guiding effective vaccination and screening strategies. This study aimed to assess the prevalence and distribution of HPV genotypes among unvaccinated women aged 30 years and older undergoing routine screening in Ankara. It also aimed to compare the frequencies of genotypes included and not included in current vaccines and to investigate their association with cervical smear cytology. Methods: This descriptive, cross-sectional, single-center study was conducted at Ankara Etlik City Hospital between 15 November 2024 and 15 February 2025. A total of 500 sexually active, unvaccinated women aged 30 years or older were enrolled. Cervical swab samples were analyzed for HPV DNA and genotypes using real-time PCR (28-type panel), and cytology results were retrospectively obtained from medical records. Results: HPV infection was detected in 18.2% of participants. Among HPV-positive women, 71.4% had single-type and 28.6% had multiple-type infections. The most common high-risk genotypes among HPV-positive individuals were HPV 16 (13.2%), HPV 18 (13.2%), and HPV 59 (13.2%). While 35.2% of HPV-positive cases included genotypes covered by the nonavalent vaccine, 64.8% involved at least one genotype not covered, mainly HPV 59, 44, and 51. HPV was detected in 17% of individuals with normal cytology, 19% of those with atypical squamous cells of undetermined significance (ASC-US), and 100% of cases with low-grade squamous intraepithelial lesion (LSIL) (p < 0.001). Conclusions: The findings emphasize the persistence of high-risk and non-vaccine-covered HPV types in the population, highlighting the need for updated vaccination policies and the development of broader-spectrum vaccines aligned with local genotype profiles. Full article
(This article belongs to the Special Issue HPV Vaccination and Primary HPV Screening)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop